Gastric Outlet Obstruction (GOO): Management
1. Initial Resuscitation (all patients)
- NG tube decompression to rest the stomach and reduce vomiting/aspiration risk
- IV fluid resuscitation - the classic finding is hypochloremic, hypokalemic metabolic alkalosis from repeated vomiting of HCl and K+. Correct with isotonic (0.9%) saline plus potassium chloride - this is essential before any surgery (Bailey and Love's Short Practice of Surgery, p. 1190).
- Nutritional support if obstruction prolonged (NG feeding or TPN)
- Correct anemia if present
2. Diagnostic Workup
- Upper endoscopy with biopsy is mandatory to exclude malignancy - with declining peptic ulcer incidence, GOO should be considered malignant until proven otherwise (Bailey and Love's, p. 1189-1190).
- CT abdomen to assess extent/resectability if malignant cause suspected.
3. Definitive Treatment - depends on cause
Benign causes (chronic duodenal ulcer scarring, most common benign cause):
- Aggressive medical therapy first: high-dose PPI, H. pylori eradication - can resolve edema/inflammation-driven components and may delay/avoid surgery for 1-2 years in roughly half of patients (Current Surgical Therapy 14e, p. 132-133).
- Endoscopic balloon dilation of the stricture - effective for benign fibrotic stenosis, often repeated.
- If medical/endoscopic therapy fails or obstruction is fixed/fibrotic: surgery
- Vagotomy and drainage - pyloroplasty or gastrojejunostomy (the traditional definitive approach)
- Antrectomy with vagotomy (Billroth I/II) in select stable patients
- Simple gastrojejunostomy bypass if dense scarring precludes safe pyloroplasty
Malignant causes (gastric cancer, pancreatic cancer, duodenal/ampullary cancer):
- If resectable and patient fit -> surgical resection (gastrectomy) with curative intent.
- If unresectable/palliative, three options are compared in the literature:
- Endoscopic self-expanding metal stent (SEMS) placement - faster symptom relief, shorter hospital stay, lower morbidity, but higher rates of stent obstruction/re-intervention and shorter patency, especially with longer survival.
- Surgical gastrojejunostomy (open or laparoscopic) - better long-term patency and fewer re-interventions, but higher initial morbidity and slower return to oral intake; preferred in patients with better prognosis/longer expected survival.
- EUS-guided gastroenterostomy (EUS-GE) - a newer minimally invasive option combining strong patency (comparable to surgical GJ) with less invasiveness than open surgery, though technically demanding.
Recent meta-analyses support individualizing choice by expected survival: stenting for very limited prognosis (faster relief, less morbidity), surgical or EUS-guided gastroenterostomy for patients likely to survive longer (better durability, lower re-intervention rates). Relevant systematic reviews: a 2024 review comparing EUS-GE vs. duodenal stenting (PMID: 39465748), a 2023 meta-analysis of surgical gastrojejunostomy vs. endoscopic stenting for malignant GOO (PMID: 36138247), and a 2023 meta-analysis of endoscopic stenting vs. surgery (PMID: 36869171) - these are consistent with, and update, the surgical/endoscopic comparisons in the standard textbooks.
Summary
- Resuscitate first: NG decompression + isotonic saline/KCl for the alkalosis.
- Biopsy to rule out cancer - never assume benign.
- Benign: PPI/H. pylori therapy -> endoscopic dilation -> surgery (vagotomy + drainage or resection) if refractory.
- Malignant: resect if operable; if palliative, choose stent (short prognosis) vs. surgical or EUS-guided gastroenterostomy (longer prognosis, better durability).
Sources: Bailey and Love's Short Practice of Surgery, 28th ed., p. 1189-1190; Current Surgical Therapy, 14th ed., p. 132-133; Sleisenger and Fordtran's Gastrointestinal and Liver Disease.